Illumina is trading 4.05% up at $284.10, with RBC Capital’s October 5 price-target increase a likely company-specific catalyst; reporting does not confirm it drove the intraday move.
- RBC raised its target to $310 from $230 and maintained an Outperform rating.
- RBC cited an inflection in clinical sales, positive catalysts, and a modest valuation lift as tools companies are recast as AI beneficiaries.